About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality.

Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology.

Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

SUPPORTING TERRITORY N. Dakota, S. Dakota, Minnesota, Nebraska, Iowa Overview of Role: The Senior Medical Science Liaison is a field based scientific expert that strategically supports the scientific and business objectives of cancer therapeutic areas across the product life cycle.

MSLs are the primary communicators of Summit Therapeutics science within a specific geography with healthcare professionals. MSLs are the field scientific experts on Immuno-Oncology and treatment options within this therapeutic area. They combine strong business acumen, clinical expertise, market awareness, and serve as a conduit of information to a cross functional customer base internally within Summit Therapeutics.

Responsibilities

, including clinical development and pipeline support.

: Develop, execute and maintain high impact territory plans, including HCP and Investigator engagement plans in alignment with therapeutic area medical and scientific objectives with a focus on quality Support clinical development and research initiatives across development at the request of R D to include, but not limited to, site evaluation and identification, recruitment, investigator meetings, external expert identification, and involving experts to generate scientific data including investigator-sponsored trials Identify, gain access to, and develop professional customer centric based relationships with external experts in Immuno-Oncology within assigned geography Provide education relative to disease state, therapeutic landscape and Summit Therapeutics products across the product lifecycle to healthcare providers and researchers Participate, monitor, and provide insights to Summit from relevant scientific meetings in relevant geography Continuously maintain self-education on market issues/trends, product knowledge, and new therapeutic areas of interest as it pertains to specific business

, including creating awareness and rela

Senior Medical Science Liaison (ND, SD, MN, IA, NE)